- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BiomX regains compliance with NYSE American's listing rule | 1 | Seeking Alpha | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| Mo | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards | 52 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that... ► Artikel lesen | |
| 15.11. | Biomx stock plunges to 52-week low, hits $0.61 | 1 | Investing.com | ||
| 15.11. | Biomx-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,61 US-Dollar | 2 | Investing.com Deutsch | ||
| 14.11. | BiomX Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11. | BiomX GAAP EPS of -$0.31 beats by $0.19 | 1 | Seeking Alpha | ||
| 14.11. | BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates | 108 | GlobeNewswire (Europe) | BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is... ► Artikel lesen | |
| 14.11. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11. | Biomx-Aktie stürzt auf 52-Wochen-Tief von 0,72 US-Dollar | 2 | Investing.com Deutsch | ||
| 01.11. | Biomx stock plunges to 52-week low of $0.72 amid market challenges | 3 | Investing.com | ||
| 31.10. | BiomX Inc. - 15-12G, Securities registration termination | 3 | SEC Filings | ||
| 25.10. | NSE - BiomX Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 24.10. | Biomx-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,87 US-Dollar | 3 | Investing.com Deutsch | ||
| 24.10. | Biomx stock plunges to 52-week low, hits $0.87 | 1 | Investing.com | ||
| 15.10. | BiomX Announces a Mandatory Unit Separation | 107 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that... ► Artikel lesen | |
| 15.10. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.10. | Biomx stock plunges to 52-week low, hitting $0.92 | 1 | Investing.com | ||
| 26.09. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | BiomX Stock Gains From Favorable Study Data Presentation on BX004 | 1 | Zacks |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,80 | +0,09 % | BioTech-Übernahmen 2025, jetzt sind mehrere 100 % angesagt: Evotec, Vidac Pharma, BioNTech und Pfizer | Zwei Versuche gab es bereits, aber die Story geht weiter! Evotec-Spekulanten sahen sich im November mit einer üppigen Gerüchteküche und einem Übernahme-Angebot konfrontiert. Das passiert, wenn abgestürzte... ► Artikel lesen | |
| AMGEN | 252,65 | -0,36 % | Amgen Announces 2025 First Quarter Dividend | THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,980 | -3,88 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| INFLARX | 2,150 | -2,45 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,244 | -2,05 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,986 | +1,56 % | Cathie Wood's ARK buys BEAM and PACB, sells IONS stock | ||
| REDHILL BIOPHARMA | 7,120 | -0,56 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| COHERUS | 1,610 | -0,22 % | Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Large Drop in Short Interest | ||
| CURIS | 3,340 | +1,21 % | Curis-Aktie stürzt auf 52-Wochen-Tief und erreicht 3,5 US-Dollar | ||
| BIOXCEL THERAPEUTICS | 0,461 | +19,27 % | BioXcel Therapeutics stock hits 52-week low at $0.35 | ||
| ESPERION | 2,295 | +3,71 % | Esperion Therapeutics, Inc.: Esperion Partners with Neopharm to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel | - Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales - - Israel-Based Commercial Organization Brings Successful Track Record Commercializing... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,555 | -1,77 % | Adaptimmune Therapeutics PLC: First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor... ► Artikel lesen | |
| FIBROGEN | 0,310 | +0,65 % | FibroGen, Inc.: FibroGen Appoints David DeLucia as Chief Financial Officer | SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company... ► Artikel lesen | |
| KARYOPHARM | 0,633 | -1,16 % | Karyopharm Therapeutics Aktie: Versprechen mit Substanz! | Die Karyopharm Therapeutics Aktie verzeichnete am 7. Dezember einen beachtlichen Aufschwung mit einem Plus von 7,17 Prozent auf 0,77 EUR. Diese positive Entwicklung kommt zu einem Zeitpunkt, an dem... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,008 | -0,98 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.
